Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cannibble Food-Tech Ltd. (PLCN.CN)
Rosh Haayin, IL
Established in 2018 and based in Rosh HaAyin, Israel, Cannibble Food-Tech Ltd. is dedicated to the creation, production, and distribution of a unique line of premixed foods, beverages, nutritional supplements, and spices. These products are fortified with cannabidiol (CBD) and hemp protein, catering to the wellness, health, and recreational markets, specifically in Las Vegas and Nevada, United States. Operating under its flagship Pelicann brand, the company offers a diverse portfolio, including instant baking mixes like cupcake and pancake powders under CannaMix; powdered beverage solutions for hot, cold, and iced drinks via CannaShakes; Mediterranean-inspired salad and pizza seasonings through CannaSpice; hemp protein shakes within the CannaShakes Sports line; and CannaPop, an instant microwave popcorn mix. Cannibble Food-Tech's offerings are available to consumers through a wide network encompassing resellers, distributors, brick-and-mortar retail establishments, its proprietary Pelicann online stores, and various third-party e-commerce platforms.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -11.11% | -20.00% | +700.00% | +700.00% | +300.00% | -77.14% | -87.69% | -87.69% | -87.69% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-79.2% Q2'25: -100.0% (vs Q2'24)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+82.4% ★ Q2'25: +642.9% (vs Q2'24)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-1,023.8%
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-1,019.1%
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q2'25: -18.4% (vs Q2'24)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+9.2% Q2'25: +0.0% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.00× Q2'25: 0.35× (vs Q2'24)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Elad Barkan | Founder, CTO & Director | — | male |
| Gabriel Kabazo | Chief Financial Officer | — | male |
| Yoav Bar-Joseph | Founder, Chief Executive Officer & Director | — | male |
| Ziv Turner | Founder & VP of BizDev | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PLCN.CN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
